Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. The life sciences industry is right to be optimistic about the potential of generative AI. Biotech startups are already testing AI-generated drugs in clinical trials with human patients. Researchers have estimated that AI-powered drug discovery could drive as much as $50 billion in economic value over the next decade.

Just last week Microsoft announced that it had partnered with a digital pathology company, Paige, in order to build the world's largest image-based AI model for identifying cancer. The training data set for the algorithm contains 4 million images. "This is sort of a groundbreaking, land-on-the-moon kind of moment for cancer care," Paige CEO Andy Moye told CNBC. Last month, results from the first clinical trial of AI-supported breast cancer screening came out. The researchers compared two methods for reading a mammogram: a standard reading by two independent radiologists, and a system that used a single radiologist and an AI to assign patients a numerical cancer risk score from 1 to 10.

Fox News contributor Dr. Marc Siegel weighs in on how artificial intelligence can change the patient-doctor relationship on'America's Newsroom.' With research showing that only 22% of Americans keep a written record of their end-of-life wishes, a team at OSF HealthCare in Illinois is using artificial intelligence to help physicians determine which patients have a higher chance of dying during their hospital stay. The team developed an AI model that is designed to predict a patient's risk of death within five to 90 days after admission to the hospital, according to a press release from OSF. The goal is for the clinicians to be able to have important end-of-life discussions with these patients. "It's a goal of our organization that every single patient we serve would have advanced care planning discussions documented, so we could deliver the care that they wish -- especially at a sensitive time like the end of their life, when they may not be able to communicate with us because of their clinical situation," said lead study author Dr. Jonathan Handler, OSF HealthCare senior fellow of innovation, in an interview with Fox News Digital.

As a fourth-year ophthalmology resident at Emory University School of Medicine, Dr. Riley Lyons' biggest responsibilities include triage: When a patient comes in with an eye-related complaint, Lyons must make an immediate assessment of its urgency. He often finds patients have already turned to "Dr. Online, Lyons said, they are likely to find that "any number of terrible things could be going on based on the symptoms that they're experiencing." So, when two of Lyons' fellow ophthalmologists at Emory came to him and suggested evaluating the accuracy of the AI chatbot ChatGPT in diagnosing eye-related complaints, he jumped at the chance. In June, Lyons and his colleagues reported in medRxiv, an online publisher of preliminary health science studies, that ChatGPT compared quite well to human doctors who reviewed the same symptoms -- and performed vastly better than the symptom checker on the popular health website WebMD. And despite the much-publicized "hallucination" problem known to ...

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. COVID: Artificial intelligence-generated COVID drug enters clinical trials. WORK TOGETHER: Embracing AI means we must mitigate risk to firms, industries, consumers and society. TERRIFYING TECH: Criminal enterprise flaunts AI in creepy commercial meant for dark web.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. Artificial intelligence is increasingly moving into the health care arena and helping to streamline medical processes -- including the creation of new drugs. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials. This oral drug is a treatment, not a vaccine.

Breast cancer is a significant health issue in the US, with approximately 240,000 women being diagnosed with breast cancer every year, according to the Centers for Disease Control and Prevention (CDC). As a result, women are encouraged to do yearly breast screenings or mammograms to detect breast cancer early when treatment is the most effective. Now, AI can help with those screenings. A trial published in The Lancet Oncology journal performed a randomized trial with 80,000 women between the ages of 40 through 80, with a median age of 54, to compare the efficacy of AI in reading mamograms compared to standard readings by radiologists. To conduct the trial, the women who opted to participate in the study across the four screening sites in Sweden were randomly assigned to AI-supported screenings or standard double readings without AI on a 1:1 ratio, meaning half were screened by AI and the other half by radiologists.

Could you tell if you were listening to an AI-generated voice? Even when people know they may be listening to AI-generated speech, it is still difficult for both English and Mandarin speakers to reliably detect a deepfake voice. That means billions of people who understand the world's most spoken languages are potentially at risk when exposed to deepfake scams or misinformation. Kimberly Mai at University College London and her colleagues challenged more than 500 people to identify speech deepfakes among multiple audio clips. Some clips contained the authentic voice of a female speaker reading generic sentences in either English or Mandarin, while others were deepfakes created by generative AIs trained on female voices.

The use of artificial intelligence in breast cancer screening is safe and can almost halve the workload of radiologists, according to the world's most comprehensive trial of its kind. Breast cancer is the most prevalent cancer globally, according to the World Health Organization, with more than 2.3 million women developing the disease every year. Screening can improve prognosis and reduce mortality by spotting breast cancer at an earlier, more treatable stage. Preliminary results from a large study suggest AI screening is as good as two radiologists working together, does not increase false positives and almost halves the workload. The interim safety analysis results of the first randomised controlled trial of its kind involving more than 80,000 women were published in the Lancet Oncology journal.

Just off the heels of introducing Relationship Goals this year, the dating app Tinder made headlines recently because, apparently, many Tinder users are already in relationships. The claim comes from a new study in the journal Cyberpsychology, Behavior, and Social Networking, titled, "Finding Intimacy Online: A Machine Learning Analysis of Predictors of Success." The study focuses on satisfaction of Tinder use and offline dates from the app, but more people have focused on one statistic: 65.3 percent of the 1,387 survey participants reported that they were married or otherwise in a relationship. Tinder, meanwhile, calls the study bogus. Mashable reached out to both the dating app and the lead author of the study to figure out the truth.